LDL Particle Number vs. Particle Size: Why Concentration Matters More
Research (Otvos, Sniderman, et al.) · Multiple studies, including Otvos et al. (2002) and Sniderman et al. (2011) (2002)
LDL particle number (LDL-P) is a stronger predictor of cardiovascular events than LDL cholesterol or LDL particle size. Large, fluffy LDL particles are not protective; atherogenicity is driven by the total number of LDL particles, not their size.
Core Concepts
The Problem
Standard lipid panels measure LDL cholesterol, which can be discordant with the actual number of atherogenic particles, leading to undertreatment of patients with high particle counts who have normal LDL-C.
The Claim
Measuring LDL-P or apoB provides more accurate cardiovascular risk assessment than LDL-C alone, especially in individuals with metabolic syndrome or on lipid-lowering therapy.
Key Evidence
- •MRI and epidemiological studies show that when LDL-C and LDL-P are discordant, risk follows LDL-P.
- •Clinical trials like JUPITER and AIM-HIGH confirm that reducing LDL-P, not just LDL-C, reduces events.
- •Particle size carries little independent risk after adjusting for particle number.
Practical Implication
Clinicians should incorporate LDL-P or apoB into routine cardiovascular risk assessment to avoid missing high-risk patients.
Nuance & Limits
Not all large LDL are harmless; in combination with high particle number, large particles still contribute to plaque burden. The concept of 'atherogenic particle burden' replaces the size myth.
Source Material
Citation Density
high
Related Ideas
ApoB is a direct count of atherogenic particles, closely correlated with LDL-P. Both measures overcome the limitations of LDL-C.
Gaps
- ⚠ Lack of universal adoption in clinical guidelines due to cost and inertia.
- ⚠ Need for clearer cutpoints for LDL-P to guide treatment decisions.
Discuss Further
Open this concept in an AI assistant for deeper discussion, critique, or exploration.